Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854207 | 0.90 | L3MBTL1 (0.43) | CSF1RADORA2AADORA1MAPK14MEN1 | |
| SCHEMBL29902516 | 0.88 | CSF1R (0.46) | CSF1RADORA2AADORA1TGFBR1TGFBR2 | |
| SCHEMBL21753567 | 0.82 | ADORA3 (0.47) | CSF1RADORA2AADORA1MEN1KMT2A | |
| SCHEMBL23152069 | 0.77 | RECQL (0.50) | MEN1KMT2AALDH1A1RAB9AKDM4E | |
| SCHEMBL21753512 | 0.77 | KMT2A (0.39) | ADORA2AADORA1MAPK14KMT2AALDH1A1 | |
| SCHEMBL15750450 | 0.77 | MEN1 (0.43) | MEN1KMT2APTGDR2ALDH1A1RAB9A | |
| SCHEMBL2920554 | 0.76 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL21753533 | 0.76 | CSNK1D (0.47) | CSF1RMAPK14MEN1KMT2A | |
| SCHEMBL16973966 | 0.75 | NR1H4 (0.48) | ADORA2AADORA1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL21854021 | 0.74 | LMNA (0.45) | KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582418-A1 | CRYSTALLINE FORM OF QUINOLINE DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-07-09 | — | — | EP | disclosed |
| EP-3842425-B1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024046292-A1 | CRYSTALLINE FORM OF QUINOLINE DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-117624128-A | Crystal form of quinoline derivative inhibitor and preparation method and application thereof | 药捷安康(南京)科技股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-110857293-B | Novel quinoline derivative inhibitor | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-09-22 | — | — | US | disclosed |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-112625027-B | Heterocyclic derivatives and use thereof | 药捷安康(南京)科技股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4036086-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2022-08-03 | — | — | EP | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-10 | — | — | US | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842425-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-06-30 | — | — | EP | disclosed |
| CN-112625027-A | Heterocyclic derivatives and use thereof | 南京药捷安康生物科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2021057782-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-110857293-A | Novel quinoline derivative inhibitor | 南京药捷安康生物科技有限公司 | 2020-03-03 | — | — | CN | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
| WO-2020038460-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | 南京药捷安康生物科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073496-A1 | NOVEL QUINOLINE DERIVATIVE INHIBITOR | CSF1R, CSF3R, FLT3 | CSF1R 1/4885ADORA2A 2164/4885ADORA1 1536/4885 |
| US-20220298146-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | RET, MERTK, MIF | CSF1R 135/4885ADORA2A 1605/4885ADORA1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.